NRIX Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -1094.77% compared to Nurix Therapeutics, Inc.'s net margin of 39.21%. Nurix Therapeutics, Inc.'s return on equity of -55.52% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Nurix Therapeutics, Inc. has a consensus price target of $27.35, signalling upside risk potential of 39.91%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.76 which suggests that it could grow by 9.55%. Given that Nurix Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Nurix Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..

Nurix Therapeutics, Inc. has a beta of 1.874, which suggesting that the stock is 87.383% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Nurix Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.63% to investors and pays a quarterly dividend of $0.79 per share. Nurix Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Nurix Therapeutics, Inc. quarterly revenues are $7.9M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Nurix Therapeutics, Inc.'s net income of -$86.4M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Nurix Therapeutics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics, Inc. is 19.27x versus 5.16x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -1094.77% compared to Nurix Therapeutics, Inc.'s net margin of --. Nurix Therapeutics, Inc.'s return on equity of -55.52% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Nurix Therapeutics, Inc. has a consensus price target of $27.35, signalling upside risk potential of 39.91%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1150%. Given that GT Biopharma, Inc. has higher upside potential than Nurix Therapeutics, Inc., analysts believe GT Biopharma, Inc. is more attractive than Nurix Therapeutics, Inc..

Nurix Therapeutics, Inc. has a beta of 1.874, which suggesting that the stock is 87.383% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Nurix Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nurix Therapeutics, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Nurix Therapeutics, Inc. quarterly revenues are $7.9M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Nurix Therapeutics, Inc.'s net income of -$86.4M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Nurix Therapeutics, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics, Inc. is 19.27x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

KalVista Pharmaceuticals, Inc. has a net margin of -1094.77% compared to Nurix Therapeutics, Inc.'s net margin of -361.39%. Nurix Therapeutics, Inc.'s return on equity of -55.52% beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.

Nurix Therapeutics, Inc. has a consensus price target of $27.35, signalling upside risk potential of 39.91%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 91.83%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Nurix Therapeutics, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Nurix Therapeutics, Inc..

Nurix Therapeutics, Inc. has a beta of 1.874, which suggesting that the stock is 87.383% more volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.

Nurix Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nurix Therapeutics, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nurix Therapeutics, Inc. quarterly revenues are $7.9M, which are smaller than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. Nurix Therapeutics, Inc.'s net income of -$86.4M is lower than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, Nurix Therapeutics, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics, Inc. is 19.27x versus 56.06x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -1094.77% compared to Nurix Therapeutics, Inc.'s net margin of 21.32%. Nurix Therapeutics, Inc.'s return on equity of -55.52% beat Pfizer Inc.'s return on equity of 10.84%.

Nurix Therapeutics, Inc. has a consensus price target of $27.35, signalling upside risk potential of 39.91%. On the other hand Pfizer Inc. has an analysts' consensus of $29.08 which suggests that it could grow by 14.65%. Given that Nurix Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Nurix Therapeutics, Inc. is more attractive than Pfizer Inc..

Nurix Therapeutics, Inc. has a beta of 1.874, which suggesting that the stock is 87.383% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Nurix Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.67% to investors and pays a quarterly dividend of $0.43 per share. Nurix Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Nurix Therapeutics, Inc. quarterly revenues are $7.9M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Nurix Therapeutics, Inc.'s net income of -$86.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Nurix Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics, Inc. is 19.27x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.